Trevi Therapeutics Reports Officer and Director Changes
Ticker: TRVI · Form: 8-K · Filed: Aug 20, 2025 · CIK: 1563880
Sentiment: neutral
Topics: leadership-change, corporate-governance
Related Tickers: TRVI
TL;DR
Trevi Therapeutics (TRVI) filed an 8-K for officer/director changes on Aug 14.
AI Summary
Trevi Therapeutics, Inc. filed an 8-K on August 20, 2025, reporting events as of August 14, 2025. The filing indicates changes related to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements for certain officers. Specific details regarding the individuals involved, their roles, and the nature of the compensatory arrangements are not provided in this excerpt.
Why It Matters
Changes in a company's board of directors or executive officers can signal shifts in strategy, governance, or operational focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in key leadership roles can introduce uncertainty and signal potential strategic shifts, requiring closer monitoring by investors.
Key Players & Entities
- Trevi Therapeutics, Inc. (company) — Registrant
- August 14, 2025 (date) — Date of earliest event reported
- August 20, 2025 (date) — Date of report
FAQ
What specific changes occurred regarding directors or officers at Trevi Therapeutics?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, as well as changes to compensatory arrangements for certain officers.
When were these changes effective or reported?
The earliest event reported was on August 14, 2025, and the report was filed on August 20, 2025.
What is Trevi Therapeutics' principal executive office address?
The principal executive offices are located at 195 Church Street, 16th Floor, New Haven, Connecticut 06510.
What is Trevi Therapeutics' telephone number?
The company's telephone number, including area code, is (203) 304-2499.
What is Trevi Therapeutics' SIC code?
The Standard Industrial Classification code for Trevi Therapeutics is 2834, Pharmaceutical Preparations.
Filing Stats: 648 words · 3 min read · ~2 pages · Grade level 13.3 · Accepted 2025-08-20 16:31:26
Key Financial Figures
- $0.001 — e on which registered Common stock, $0.001 par value per share TRVI The Nasdaq
Filing Documents
- trvi-20250814.htm (8-K) — 53KB
- 0001563880-25-000005.txt ( ) — 162KB
- trvi-20250814.xsd (EX-101.SCH) — 28KB
- trvi-20250814_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TREVI THERAPEUTICS, INC. Date: August 20, 2025 By: /s/ Jennifer L. Good Name: Jennifer L. Good Title: President and Chief Executive Officer